Nathan Zammit

Nathan is a Senior Scientist in the Discovery Research team at GentiBio. Nathan completed a PhD and postdoctoral work at the Garvan Institute & University of New South Wales in Sydney, Australia, where he devised an approach to engender pancreatic islet allograft tolerance by the upregulation of an endogenous defense gene, A20. These studies contributed to progression to a first in human safety and efficacy trial for a gene therapy product, and uncovered a molecular toggle utilized to balance evolutionary disease tolerance vs resistance mechanisms during human evolution. Following his interest in inflammation and cell/gene therapy, Nathan joined the Mathis/Benoist lab at Harvard Medical School, where he completed a postdoc characterizing novel populations of Treg cells within thermogenic brown adipose tissue. Nathan is excited to continue his research into Treg cells and to leverage their immunotherapeutic potential at Gentibio. Outside the lab Nathan enjoys spending time exploring the outdoors, immersing himself in ancient history and experimenting with cooking/cheesemaking.